GSK heads into its May 6 Q1 results carrying sharply higher short positioning — yet the borrow market tells a more nuanced story than the headline shorts figure suggests.
Short interest on the NYSE-listed ADR has climbed roughly 36% over the past month to 16.6 million shares. The move is real and accelerating. But availability in the lending pool remains moderate: borrow costs have eased back to 0.52% from a mid-April peak near 0.68%, and the borrow market is far from stressed. That combination — rising shorts, loose borrow — points to deliberate directional positioning rather than a squeeze dynamic.
Options traders are leaning the other way. The put/call ratio has fallen to 0.52, about 1.5 standard deviations below its 20-day average of 0.55, suggesting calls are dominating options flow heading into the print. That reads as incrementally bullish positioning on a near-term basis — a notable divergence from the short interest build-up and worth flagging rather than smoothing over.
The fundamental debate centres on pipeline durability versus patent headwinds. Recent news flagged that GSK delivered a "strong Q1 2026 performance," and the stock initially rallied sharply after the February Q4 print — rising 10.9% on the day. But the April 29 Q1 release, already in the books, saw the stock fall nearly 4%, and the share price is down 6.5% over the past month to $51.61. That post-print weakness has attracted the short build. On valuation, the PE multiple has compressed to around 10.6x, down nearly a full turn over the past month, while EV/EBITDA has nudged higher to 14.4x — a mild divergence suggesting earnings estimates may be drifting down even as the EV holds. JP Morgan, notably, retained an Underweight on the LSE-listed shares this week with a £17 target, calling upgrade potential limited. The earlier Barclays downgrade to Underweight (January 2026) reinforced that bearish analyst cluster — though most older price targets in USD are stale relative to today's price and should be treated with caution.
Institutionally, BlackRock added over 41 million ADR shares in its most recent filing, lifting its stake to nearly 10%. Fidelity (FMR LLC) also added 47 million shares, a material increase. Those are meaningful flow signals against the backdrop of short-seller accumulation.
The May 6 print — covering a fresh reporting period — will test whether GSK can sustain the pipeline momentum that drove February's outsized rally, or whether patent-cliff concerns and limited earnings upgrade potential leave the stock without a catalyst to absorb the growing short base.
See the live data behind this article on ORTEX.
Open GSK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
